Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
AbbVie (DE:4AB)
XETRA:4AB
Holding DE:4AB?
Track your performance easily
4AB Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€141.98 - €192.50
Previous Close€175.28
Volume569.00
Average Volume (3M)2.43K
Market Cap
€310.51B
Enterprise Value€372.40B
Total Cash (Recent Filing)$7.29B
Total Debt (Recent Filing)$71.08B
Price to Earnings (P/E)66.3
Beta-0.03
Next Earnings
Jan 31, 2025EPS Estimate
€2.89Next Dividend Ex-Date
Jan 15, 2025Dividend Yield3.42%
Share Statistics
EPS (TTM)2.64
Shares Outstanding1,767,140,323
10 Day Avg. Volume1,667
30 Day Avg. Volume2,427
Standard Deviation0.07
R-Squared0.04
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)51.40
Price to Sales (P/S)5.77
Price to Cash Flow (P/CF)14.70
P/FCF Ratio14.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue6.71
Enterprise Value/Gross Profit10.98
Enterprise Value/Ebitda20.46
Forecast
1Y Price Target
€196.59Price Target Upside12.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering19
AbbVie News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceAbbVie's core growth drivers remain intact, with a strong performance in the core portfolio and potential for additional business development.
Market PositionAbbVie is considered one of the best-positioned names in large-cap coverage, with a core business trending ahead of expectations and attractive valuation.
Product InnovationAbbVie's newer agents, Skyrizi and Rinvoq, are offsetting the volume declines of Humira and are gaining prescriber preference over biosimilars.
Bears Say
Acquisition ChallengesThe update represents negative optics after the company's $9bn acquisition of Cerevel, for which it now has limited value to show.
Drug DevelopmentAbbVie announced that emraclidine’s pivotal Phase 2 trials did not meet their primary endpoints.
Financial GuidanceManagement lowered 2024 aesthetics guidance to $5.3bn from $5.5bn, with a notable reduction in Juvederm sales expectations.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.08% Insiders
21.89% Mutual Funds
0.32% Other Institutional Investors
56.22% Public Companies and
Individual Investors
4AB FAQ
What was AbbVie’s price range in the past 12 months?
AbbVie lowest stock price was €141.98 and its highest was €192.50 in the past 12 months.
What is AbbVie’s market cap?
Currently, no data Available
When is AbbVie’s upcoming earnings report date?
AbbVie’s upcoming earnings report date is Jan 31, 2025 which is in 26 days.
How were AbbVie’s earnings last quarter?
AbbVie released its earnings results on Oct 30, 2024. The company reported €2.909 earnings per share for the quarter, beating the consensus estimate of €2.831 by €0.078.
Is AbbVie overvalued?
According to Wall Street analysts AbbVie’s price is currently Undervalued.
Does AbbVie pay dividends?
AbbVie pays a Quarterly dividend of €1.589 which represents an annual dividend yield of 3.42%. See more information on AbbVie dividends here
What is AbbVie’s EPS estimate?
AbbVie’s EPS estimate is €2.89.
How many shares outstanding does AbbVie have?
AbbVie has 1,767,140,400 shares outstanding.
What happened to AbbVie’s price movement after its last earnings report?
AbbVie reported an EPS of €2.909 in its last earnings report, beating expectations of €2.831. Following the earnings report the stock price went up 4.067%.
Which hedge fund is a major shareholder of AbbVie?
Among the largest hedge funds holding AbbVie’s share is Diamond Hill Capital Management Inc. It holds AbbVie’s shares valued at 260M.
---
AbbVie Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€196.59 (12.16% Upside)
€196.59 (12.16% Upside)
Blogger Sentiment
Bullish
DE:4AB Sentiment 94%
Sector Average 71%
Sector Average 71%
Insider Transactions
Sold Shares
Worth $310.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
17.06%
12-Months-Change
Fundamentals
Return on Equity
56.06%
Trailing 12-Months
Asset Growth
5.29%
Trailing 12-Months
Company Description
AbbVie
AbbVie, Inc. is a biopharmaceutical company focused on key therapeutic areas like immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
---
4AB Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
AbbVie demonstrated strong commercial, operational, and R&D execution with significant growth from its ex-HUMIRA platform, increased revenue and EPS guidance, and successful acquisition and integration of Cerevel Therapeutics. However, challenges remain with declining HUMIRA sales, aesthetic market headwinds, and competitive pressures on IMBRUVICA.Read More>---
4AB Net revenue Breakdown
48.12% Immunology
14.21% Neuroscience
12.59% Other Key Products
10.89% Oncology
14.19% Other
---
4AB Stock 12 Month Forecast
Average Price Target
€196.59
▲(12.16% Upside)
Technical Analysis
Best Analysts Covering 4AB
1 Year
1 Year Success Rate
35/40 ratings generated profit
1 Year Average Return
+21.59%
reiterated a buy rating 20 days ago
Copying Christopher Raymond's trades and holding each position for 1 Year would result in 87.50% of your transactions generating a profit, with an average return of +21.59% per trade.
---